RE:RE:Positive Histology Results From Pivotal Preclinical studyAnd soon they will start the phase 1 clinical trial with placebo control. Within 24 months, results will be out and if result are as good as on the animal model, the market cap will jump 25 X.
This is a phase 1 but still, if results shows a great improvment on the recovery of rotary cuff surgery between the group with Ortho-R and the placebo control study, then this will move strongly.
And this phase 1 is for rotary cuff repair, buth Ortho-R is a platform that is effective for tendons, meniscus and ligament. So the actual phase 1 will likely be a done deal for the other indications once completed if succesfull. So an even larger market.
And the other great thing about the Chitosan based matrix comes in a powder with 24 months shelves life and can be prepaired before the operation by mixing it with the patient platelet. It only add 5 minutes to the rotary cuff operation so it is not costly in labor time and very safe as the active componet is the patient platelet.
Study have proven that platelet applied in-situ help the recovery, however, they barely last 24 hours.
With Ortho-R Chitosan based matrix, Platelet stays in-situ for more than 6 weeks helping for a complete recovery.
This is a game changer.
From their website: Ortho-R is a
proprietary RESTORE technology platform, is a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as Platelet-Rich Plasma (PRP) or Bone Marrow Aspirate Concentrate (BMAC), to augment and guide the regeneration of new tissue in various musculoskeletal conditions. Ortho-R, our lead Chitosan-PRP hybrid biologic implant product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, meniscus and ligaments. Other formulations are being developed for cartilage repair, bone void filling and osteoarthritis treatment. The polymer-biologics hybrid combination can be directly applied into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Our commercialization strategy involves a rapid development of treatments for both rotator cuff injuries in the shoulder and meniscus injuries of the knee joint, with an initial focus on the highly developed US Sports Medicine market. Other countries will follow shortly thereafter.
I am a shareholder of Ortho.